Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study

Cholangiocarcinoma Clinical Trial

— PET/MRCP  

Official title:

Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00604266
• Other study ID #: 07-0216
• Status: Withdrawn
• Phase: N/A
• First received: January 17, 2008
• Last updated: May 1, 2017
• Start date: August 2007
• Est. completion date: August 2008

Study information

• Verified date: May 2017
• Source: University of Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To evaluate the feasibility and performance of coregistered 18F-FDG-PET/MRI in the staging of potentially respectable hilar cholangiocarcinoma.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 2008
• Est. primary completion date: August 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Hilar cholangiocarcinoma assessed by conventional imaging modalities (triphasic CT scan of the liver) and thought to be potentially resectable.

Exclusion Criteria:

• Biliary drain inserted.

• Contraindication for MRI.

• Pregnant or breast-feeding.

• Uncontrolled diabetes (over 9.7 mmol/L).

Related Conditions & MeSH terms

• Cholangiocarcinoma
• Klatskin Tumor

Locations

Country	Name	City	State
Canada	UHN - Princess Margaret Hospital	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
University of Toronto	University Health Network, Toronto

Country where clinical trial is conducted

Canada,